Sanofi's next-generation insulin shows edge over Lantus

PARIS, June 24:� An improved version of Sanofi's� blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday. The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the 43 billion dollar diabetes market from rival drugs. (agencies)